Quick Takeaways
- This page summarizes Robert E. Waltermire's Form 4 filing for MADRIGAL PHARMACEUTICALS, INC. (MDGL).
- 10 reported transactions and 2 derivative rows are listed below.
- Filing timestamp: 02 Mar 2023, 15:30.
Robert E. Waltermire - 28 Feb 2023 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)
- Signature
- /s/ Brian J. Lynch
- Issuer symbol
- MDGL
- Transactions as of
- 28 Feb 2023
- Net transactions value
- -$1,853,238
- Form type
- 4
- Filing time
- 02 Mar 2023, 15:30:31 UTC
- Previous filing
- 18 Jan 2023
- Next filing
- 14 Dec 2023
- SEC
- View on sec.gov
Quoteable Key Fact
"Robert E. Waltermire filed Form 4 for MADRIGAL PHARMACEUTICALS, INC. (MDGL) on 02 Mar 2023."
What Changed
- Previous filing in this sequence was filed on 18 Jan 2023.
- Current net transaction value: -$1,853,238.
Why This Matters
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Source Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Transactions Table
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MDGL | Common Stock | Options Exercise | $439,600 | +5,000 | +88% | $87.92 | 10,667 | 28 Feb 2023 | Direct | |
| transaction | MDGL | Common Stock | Sale | $243,927 | -900 | -8.4% | $271.03 | 9,767 | 28 Feb 2023 | Direct | F2 |
| transaction | MDGL | Common Stock | Sale | $1,116,430 | -4,100 | -42% | $272.30 | 5,667 | 28 Feb 2023 | Direct | F3 |
| transaction | MDGL | Common Stock | Options Exercise | $439,600 | +5,000 | +88% | $87.92 | 10,667 | 01 Mar 2023 | Direct | |
| transaction | MDGL | Common Stock | Sale | $527,192 | -1,928 | -18% | $273.44 | 8,739 | 01 Mar 2023 | Direct | F4 |
| transaction | MDGL | Common Stock | Sale | $459,081 | -1,672 | -19% | $274.57 | 7,067 | 01 Mar 2023 | Direct | F5 |
| transaction | MDGL | Common Stock | Sale | $358,189 | -1,300 | -18% | $275.53 | 5,767 | 01 Mar 2023 | Direct | F6 |
| transaction | MDGL | Common Stock | Sale | $27,619 | -100 | -1.7% | $276.19 | 5,667 | 01 Mar 2023 | Direct |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MDGL | Stock Option (Right to Buy) | Options Exercise | $0 | -5,000 | -14% | $0.000000 | 30,000 | 28 Feb 2023 | Common Stock | 5,000 | $87.92 | Direct | F1 |
| transaction | MDGL | Stock Option (Right to Buy) | Options Exercise | $0 | -5,000 | -17% | $0.000000 | 25,000 | 01 Mar 2023 | Common Stock | 5,000 | $87.92 | Direct | F1 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | All shares issued pursuant to the exercise of the options reported herein represent 10,000 shares underlying an overall option award of 35,000 shares. All exercised options had vested. As to the overall option for 35,000 shares, 25% of the shares underlying the option vested on August 2, 2022 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date. |
| F2 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $270.58 to $271.47, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below. |
| F3 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $271.82 to $272.77, inclusive. |
| F4 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $273.00 to $274.00, inclusive. |
| F5 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $274.06 to $274.99, inclusive. |
| F6 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $275.18 to $276.18, inclusive. |
Remarks:
As attorney-in-fact for Reporting Person